Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

This study is testing whether adding toripalimab — an immunotherapy drug that helps the immune system attack cancer — to standard chemotherapy and radiation can improve outcomes for patients whose nasopharyngeal cancer (cancer at the back of the nose/throat) has come back and cannot be removed with surgery. **You may be eligible if:** - You have confirmed recurring nasopharyngeal cancer (confirmed by biopsy) - Your cancer came back more than 12 months after finishing your first round of radiation - Your cancer has not spread to distant organs - Your general health score (Karnofsky) is 70 or above - Your blood, liver, and kidney test results are within acceptable ranges **You may NOT be eligible if:** - Your cancer could potentially be surgically removed - You have severe radiation-related complications such as tissue death in the throat or brain injury from prior radiation - You have an active autoimmune disease - You have another active cancer - You have a known allergy to the study medications - You have a history of significant psychiatric illness or substance abuse Talk to your doctor to see if this trial is right for you.